Evidence map›Paper›PMID 42297751›Full record

Observational studyDiabetes, obesity & metabolism2026

Weight Changes With Lower Doses of Semaglutide in Clinical Practice: Findings From the Chinese HARMONY Cohort.

Shuang Liu, Baige Cao, Chuwen Lin, Weijiong Chen, Panpan Yang, Yu Luo, Jinfang Xu, Congrong Wang

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shuang LiuDepartment of Endocrinology & Metabolism, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Baige CaoDepartment of Endocrinology & Metabolism, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Chuwen LinDepartment of Endocrinology & Metabolism, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Weijiong ChenDepartment of Endocrinology & Metabolism, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Panpan YangDepartment of Diagnostic Radiology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Yu LuoDepartment of Diagnostic Radiology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Jinfang XuDepartment of Health Statistics, Naval Medical University, Shanghai, China.
Congrong WangDepartment of Endocrinology & Metabolism, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID https://orcid.org/0000-0002-8645-1114

Funding

Clinical Key Supporting Project of Health Commission of Shanghai Hongkou District HKLCFC 202403National Natural Science Foundation of China 82070913Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0509206
6 · The paper itself

Abstract

introductionTo evaluate 24-week weight changes with lower-dose semaglutide in routine care among Chinese adults with obesity and to examine whether diabetes and ectopic fat in the liver and pancreas are associated with heterogeneity in weight-loss response. MATERIALS AND

methodsAdults with obesity were enrolled from the HARMONY study, a real-world observational cohort in China. Participants received once-weekly subcutaneous semaglutide, titrated to a maintenance dose (0.5 or 1.0 mg) based on clinical response and tolerability, alongside lifestyle counselling and periodic metabolic monitoring. The primary endpoint was the percentage change in body weight from baseline at weeks 12 and 24. Subgroup analyses were conducted according to baseline type 2 diabetes status and ectopic fat status in the liver and pancreas.

resultsOverall, 143 participants were included at week 12 and 113 at week 24. Mean percent weight change was -7.3% at week 12 and -9.9% at week 24, corresponding to mean absolute weight losses of 6.7 and 9.1 kg, respectively. By week 24, 76.1% of participants achieved 5% weight loss or more. At week 24, participants with type 2 diabetes experienced lower weight change than those without diabetes (-7.4% vs. -12.4%, p < 0.001). Weight loss also differed by baseline intrapancreatic fat deposition (IPFD) status, with attenuated weight change among patients with baseline IPFD (-9.0% with IPFD vs. -11.6% without IPFD, p = 0.043). DISCUSSION: In routine clinical care, lower doses of semaglutide were associated with clinically meaningful 24-week weight loss in Chinese adults with obesity.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsObesityWeight LossAdultAgedChinaCohort StudiesDose-Response Relationship, DrugEast Asian PeopleFemaleHumansMaleMiddle AgedSemaglutideGlucagon-Like PeptidesHypoglycemic AgentsSemaglutideGLP‐1obesity therapyobservational studyweight management

Identifiers

PMID42297751
PMCPMC13449065

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.